Caladrius Biosciences to Host 2015 Fourth Quarter and Full Year Financial Results Conference Call on March 15 at 5:00 pm Eastern Time

BASKING RIDGE, N.J., March 08, 2016 -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius”), a cell therapy company combining an industry-leading development and manufacturing services provider with a therapeutic development pipeline, announces today that the Company will release financial results for the fourth quarter and full year of 2015 after the U.S. financial markets close on Tuesday, March 15, 2016.

Caladrius’ management will host a conference call for the investment community beginning at 5:00 pm ET on Tuesday, March 15, 2016, to discuss the financial results and to answer questions.

Shareholders and other interested parties may participate in the conference call by dialing (877) 562-4460 (US) or (513) 438-4106 (International) and entering passcode 95709216. The call will also be broadcast live on the Internet via the Company’s website at www.caladrius.com/events.

The call will be archived on the Company’s website for 90 days at www.caladrius.com/events.

About Caladrius Biosciences
Caladrius Biosciences, Inc., through its wholly-owned subsidiary, PCT, is a leading development and manufacturing partner to the cell therapy industry.  Caladrius works with its clients to overcome the fundamental challenges of cell therapy manufacturing by providing a wide range of innovative services including product and process development, GMP manufacturing, engineering and automation, cell and tissue processing, logistics, storage and distribution, as well as expert consulting and regulatory support.  Around this core expertise, Caladrius strategically develops select product candidates, which currently includes an innovative therapy for type 1 diabetes based on a proprietary platform technology for immunomodulation. For more information, visit www.caladrius.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements regarding our expected revenues and capital expenditures, personnel reductions, as well as the potential of CLBS03 in the treatment of recent-onset type 1 diabetes and the expected cost savings associated with the termination of the CLBS20 study. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 2, 2015, and in the Company’s other periodic filings with the SEC. The Company’s further development is highly dependent on, among other things, future medical and research developments and market acceptance, which are outside of its control.

CONTACTS:

Investors:
LHA
Anne Marie Fields
Senior Vice President
Phone: +1-212-838-3777
Email: [email protected]

Media: 
Caladrius Biosciences, Inc.
Eric Powers
Manager of Communications and Marketing
Phone: +1-212-584-4173
Email: [email protected]